AbCellera Biologics (ABCL) Non-Current Deffered Revenue (2020 - 2025)

AbCellera Biologics has reported Non-Current Deffered Revenue for 6 years, with the latest figure at $5.8 million in Q3 2025.

• For the quarter ending Q3 2025, Non-Current Deffered Revenue fell 27.78% year-over-year to $5.8 million; the trailing twelve-month figure through Sep 2025 stood at $5.8 million (down 27.78% YoY), and the FY2024 full-year result was $5.7 million, down 30.45% from the prior year.
• Non-Current Deffered Revenue for Q3 2025 stood at $5.8 million, down from $11.6 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $64.8 million in Q2 2022, with the low at $5.7 million in Q4 2024.
• Historically, Non-Current Deffered Revenue has averaged $27.0 million across 5 years, with a median of $19.5 million in 2022.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue surged 123.29% — and 2023, when it plunged 73.66%.
• AbCellera Biologics' Non-Current Deffered Revenue stood at $27.4 million in 2021, then fell by 28.8% to $19.5 million in 2022, then plunged by 58.01% to $8.2 million in 2023, then sank by 30.45% to $5.7 million in 2024, then gained by 2.63% to $5.8 million in 2025.
• The last three Non-Current Deffered Revenue figures came in at $5.8 million (Q3 2025), $11.6 million (Q2 2025), and $13.8 million (Q1 2025), per Business Quant data.